Diamante develops plant-based peptide drugs that re-educate the human immune system to restore self-tolerance in patients with rheumatoid arthritis. This approach offers a safer, scalable, and cost-effective alternative to existing treatments, which often cause general immunosuppression and severe side effects.
Funding
$990K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
EAFounders
Product
Problem
Current rheumatoid arthritis treatments often cause general immunosuppression and severe side effects, while a significant percentage of patients do not respond to existing drugs. These treatments can compromise the immune system's ability to defend against other threats.
Solution
Diamante is developing plant-based peptide drugs designed to re-educate the human immune system and restore self-tolerance in patients with rheumatoid arthritis. This approach aims to provide a safer, more scalable, and cost-effective alternative to traditional treatments. By restoring self-tolerance, the drugs intend to address the underlying cause of rheumatoid arthritis without broadly suppressing the immune system. The company's lead asset is a specific rheumatoid arthritis drug expected to enter clinical trials in 2026.
Target Audience
The primary target audience includes patients with rheumatoid arthritis and healthcare providers seeking safer and more effective treatment options.
Features
- Plant-based peptide drugs for targeted immune modulation
- Designed to restore self-tolerance in rheumatoid arthritis patients
- Aims to avoid general immunosuppression and severe side effects associated with current treatments
- Utilizes a scalable and cost-effective production platform
- Lead asset is a specific rheumatoid arthritis drug